PO-0730: Stereotactic ablative radiotherapy (SABR) of primary and metastatic renal lesions for patients with single kidney
Radiotherapy and Oncology
consecutive prostate cancer patients were treated with IG-VMAT to a dose of 76 Gy with daily correction of the target position based on cone-beam CT imaging. The IPSS and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 toxicity were prospectively scored before VMAT, at the end of VMAT, 1, 3, 6, 12, 18, 24 and 36 months after VMAT. IPSS resolution was defined as a return to within 1 point of the score at baseline. Clinical, treatment-related parameters were evaluated included
... evaluated included patient age, alpha-blocker use, androgen deprivation therapy (ADT) use, body mass index, diabetes, hypertension, smoking and drinking habits, and prostate volume. Dosimetric quality indicators were also examined. Results: The median follow-up was 24.2 months (range,11.3-47.6). 134 (70.5%) patients took ADT medications. At last follow-up, 67 (35.3%) patients took alpha-blocker medications. The 2-year actuarial rate of grade 2 or greater genitourinary toxicity was 2.6%. The median (inter-quartile range) IPSS before VMAT, at the end of VMAT, 1, 3 months after VMAT and at last follow-up were 3(1-7), 9(5-12), 6(2-9), 3(1-8), and 4(1-7), respectively. The IPSS returned to baseline at a median of 3.0 months. The IPSS of 49 patients (25.8%) didn't exceed baseline+2 throughout the follow up. In Cox regression analysis, only drinking habit was associated with increased IPSS exceed baseline+2 (95% CI 0.283-0.907, p=0.022). Conclusions: In IG-VMAT, IPSS resolved within 3 months substantially, and late GU toxicity was very low. Cessation of drinking during radiotherapy may be useful for further improvement.